Overview
Availability
- Dr Amirah Etchegaray is:
- Available for supervision
Research interests
-
Inflammatory Bowel Disease
Works
Search Professor Amirah Etchegaray’s works on UQ eSpace
2025
Journal Article
Safety, efficacy and post-endoscopic retrograde cholangiopancreatography survival in nonagenarians: a retrospective cohort study
Etchegaray, Amirah, Mudaliar, Sanjivan, Ryan, Kimberley, Hay, Karen, Hwang, Jason, Devereaux, Benedict, Appleyard, Mark and Grimpen, Florian (2025). Safety, efficacy and post-endoscopic retrograde cholangiopancreatography survival in nonagenarians: a retrospective cohort study. Internal Medicine Journal, 55 (3), 435-443. doi: 10.1111/imj.16652
2025
Journal Article
Endosonographically confirmed Type III Choledochal Cyst Managed with Endoscopic Needle Knife Division
Etchegaray, Amirah, Mudaliar, Sanjivan and Devereaux, Benedict (2025). Endosonographically confirmed Type III Choledochal Cyst Managed with Endoscopic Needle Knife Division. VideoGIE. doi: 10.1016/j.vgie.2025.03.035
2025
Journal Article
Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series
Etchegaray, Amirah, Tambakis, George, Kumar, Rina, Croft, Anthony, Radford-Smith, Graham and Walker, Gareth J. (2025). Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series. Therapeutic Advances in Gastroenterology, 18, 1-14. doi: 10.1177/17562848251323511
2024
Conference Publication
Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series
Swe, Ei Phyu Phyu, Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2024). Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.
2024
Conference Publication
Sequential rescue therapy with Janus kinase-inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis
Etchegaray, Amirah, Tambakis, George, Croft, Anthony, Radford-Smith, Graham and Walker, Gareth (2024). Sequential rescue therapy with Janus kinase-inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.
2023
Conference Publication
Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study
Etchegaray, A., Fernandes, R., Anandan, A. Shanmuga, Selvanathan, P., Malloy, R., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
2023
Conference Publication
Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study
Anandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
2023
Conference Publication
Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience
Gilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
2023
Conference Publication
Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report
Etchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.
Supervision
Availability
- Dr Amirah Etchegaray is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Dr Amirah Etchegaray's areas of expertise, story ideas and help finding experts, contact our Media team: